MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
BIO.B — Bio-Rad Laboratories, Inc. Class B
NYSEBio-Rad Laboratories, Inc. Class B
$365.08
+28.08(+8.33%)
- O
- 365.08
- H
- 365.08
- L
- 365.08
- V
- 103.15
⏱️ End-of-day dataAs of Aug 20, 2026
Bio-Rad Laboratories, Inc. Class B Statistics
Total Valuation
| Market Cap | $1.85B |
| Enterprise Value | $1.89B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | 5.06M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.70 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 23.66 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -35.88 |
| EV / Sales | n/a |
| EV / EBITDA | 19.56 |
| EV / EBIT | -27.91 |
| EV / FCF | 24.21 |
Financial Position
| Current Ratio | 3.21 |
| Quick Ratio | n/a |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.97 |
| Debt / FCF | 1.21 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | -7.69% |
| Return on Assets (ROA) | -5.38% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-7,075 |
| Employee Count | 7,450 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -$16.27M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | +41.64% |
| 50-Day Moving Average | $294.30 |
| 200-Day Moving Average | $294.06 |
| Relative Strength Index (RSI) | 95.83 |
| Average Volume (20 Days) | 83 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | $30.94M |
| Operating Income | $34.10M |
| Pretax Income | -$68.98M |
| Net Income | -$52.71M |
| EBITDA | $96.70M |
| EBIT | -$67.75M |
| Loss Per Share | $-19.55 |
Balance Sheet
| Cash & Cash Equivalents | $50.72M |
| Total Debt | $94.15M |
| Net Cash | -$43.43M |
| Net Cash Per Share | $-8.58 |
| Equity (Book Value) | $685.13M |
| Book Value Per Share | $135.37 |
| Working Capital | $202.51M |
Cash Flow
| Operating Cash Flow | -$61.99M |
| Capital Expenditures | -$29.90M |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | $78.10M |
| FCF Per Share | $15.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 4.23% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |